Mechanistic Evaluation of Treatments for Acute Antibody-Mediated Rejection of the Kidney Transplant

Launched by IMPERIAL COLLEGE LONDON · Jul 29, 2020

Keywords

ClinConnect Summary

The TAR:GET-1 clinical trial is studying how to improve treatment for patients who have had a kidney transplant and are experiencing a complication called acute antibody-mediated rejection (AAMR). This happens when the body produces antibodies that mistakenly attack the transplanted kidney, which can shorten its lifespan. In this trial, patients will receive either the standard treatment or the standard treatment plus an additional medication called rituximab. The goal is to find out if adding rituximab can help the transplanted kidney last longer.

To participate in this trial, individuals must be UK kidney transplant patients diagnosed with AAMR and must provide informed consent to take part. Participants can expect to undergo blood tests and kidney biopsies to monitor their condition. Additionally, if they agree, they may have an extra biopsy six months after starting treatment to help researchers learn more about how AAMR treatments work. This research aims to better predict which patients will benefit most from certain treatments and ultimately improve care for kidney transplant recipients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • All patients enrolled in TAR:GET-1 Signed informed consent prior to any study specific procedures.
• Exclusion Criteria:
• • None